Literature DB >> 23483375

Clearing the air: a review of our current understanding of "chemo fog".

Erin O'Farrell1, Joyce MacKenzie, Barbara Collins.   

Abstract

An increasing number of cancer survivors has led to a greater interest in the long-term side effects of cancer treatments and their impact on quality of life. In particular, cognitive impairments have been frequently reported by cancer survivors as an adverse effect which they attribute to the neurotoxicity of chemotherapy and have dubbed "chemobrain" or "chemo fog." Research within the past 15-20 years has explored the many factors thought to contribute to cancer-related cognitive decline in an attempt to determine a potential cause. In spite of many confounding factors, there is growing evidence that the neurotoxicity of chemotherapy does contribute to cognitive changes. This review examines the evolution of "chemo fog" research with a look at methodological issues, the status of our current understanding, and suggestions for future research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23483375     DOI: 10.1007/s11912-013-0307-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  86 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

2.  A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function.

Authors:  Catherine E Jansen; Christine Miaskowski; Marylin Dodd; Glenna Dowling; Joel Kramer
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

3.  Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.

Authors:  Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Jürg Bernhard
Journal:  Breast Cancer Res Treat       Date:  2010-11-03       Impact factor: 4.872

4.  MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma.

Authors:  M S Brown; J H Simon; S M Stemmer; J C Stears; A Scherzinger; P J Cagnoni; R B Jones
Journal:  AJNR Am J Neuroradiol       Date:  1995 Nov-Dec       Impact factor: 3.825

5.  Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy.

Authors:  Nancy N Baxter; Sara B Durham; Kelly-Anne Phillips; Elizabeth B Habermann; Beth A Virning
Journal:  J Am Geriatr Soc       Date:  2009-03       Impact factor: 5.562

6.  Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy.

Authors:  Julia E Heck; Steven M Albert; Rebeca Franco; Sherri Sheinfeld Gorin
Journal:  J Am Geriatr Soc       Date:  2008-08-04       Impact factor: 5.562

7.  The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study.

Authors:  Felice A Tager; Paula S McKinley; Freya R Schnabel; Mahmoud El-Tamer; Ying Keun K Cheung; Yixin Fang; Claire R Golden; Margery E Frosch; Ulya Habif; Margaret M Mulligan; Ivy S Chen; Dawn L Hershman
Journal:  Breast Cancer Res Treat       Date:  2009-11-06       Impact factor: 4.872

8.  Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment.

Authors:  Barbara Collins; Joyce Mackenzie; Angela Stewart; Catherine Bielajew; Shailendra Verma
Journal:  Psychooncology       Date:  2009-02       Impact factor: 3.894

9.  The effects of hormone therapy on cognition in breast cancer.

Authors:  Valerie Shilling; Valerie Jenkins; Lesley Fallowfield; Tony Howell
Journal:  J Steroid Biochem Mol Biol       Date:  2003-09       Impact factor: 4.292

10.  Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response.

Authors:  Nelli Boykoff; Mona Moieni; Saskia Karen Subramanian
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

View more
  29 in total

1.  Chemotherapy-Induced Neurotoxicity: Evidence of a Protective Role of CC Homozygosis in the Interleukin-1β Gene-511 C>T Polymorphism.

Authors:  E Peila; F D'Agata; P Caroppo; L Orsi; P Mortara; S Cauda; M Manfredi; M M Caglio; P Fenoglio; B Baudino; G Castellano; G Bisi; L Pinessi; S Gallone
Journal:  Neurotox Res       Date:  2016-06-07       Impact factor: 3.911

Review 2.  Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?

Authors:  Wilbert Zwart; Huub Terra; Sabine C Linn; Sanne B Schagen
Journal:  Nat Rev Clin Oncol       Date:  2015-07-21       Impact factor: 66.675

3.  Chemo brain: From discerning mechanisms to lifting the brain fog-An aging connection.

Authors:  Anna Kovalchuk; Bryan Kolb
Journal:  Cell Cycle       Date:  2017-06-28       Impact factor: 4.534

Review 4.  Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes.

Authors:  Hilary A Marusak; Allesandra S Iadipaolo; Felicity W Harper; Farrah Elrahal; Jeffrey W Taub; Elimelech Goldberg; Christine A Rabinak
Journal:  Neuropsychol Rev       Date:  2017-12-22       Impact factor: 7.444

Review 5.  How to implement a geriatric assessment in your clinical practice.

Authors:  Schroder Sattar; Shabbir M H Alibhai; Hans Wildiers; Martine T E Puts
Journal:  Oncologist       Date:  2014-09-03

6.  Cognitive function and its relationship to other psychosocial factors in lymphoma survivors.

Authors:  Dorothy Krolak; Barbara Collins; Lorelle Weiss; Cheryl Harris; Richard Van der Jagt
Journal:  Support Care Cancer       Date:  2016-11-11       Impact factor: 3.603

Review 7.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

8.  Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey.

Authors:  John E Schmidt; Ellen Beckjord; Dana H Bovbjerg; Carissa A Low; Donna M Posluszny; Amy E Lowery; Mary Amanda Dew; Stephanie Nutt; Sarah R Arvey; Ruth Rechis
Journal:  J Cancer Surviv       Date:  2015-08-04       Impact factor: 4.442

9.  Neuropsychological profiles of breast cancer and brain tumor cohorts in Northeast Ontario, Canada.

Authors:  Matias Mariani; Mark William Glister Collins
Journal:  Support Care Cancer       Date:  2018-05-17       Impact factor: 3.603

10.  Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy.

Authors:  Masahiko Sumitani; Toru Ogata; Akina Natori; Jun Hozumi; Nobutake Shimojo; Kumiko Kida; Hideko Yamauchi; Teruo Yamauchi
Journal:  Biomed Rep       Date:  2016-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.